Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate in advanced gastric cancer
NCT02711969Phase 1Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Bukwang Pharmaceutical. Primary endpoint: Dose-limiting toxicities at 28 days. Started Mar 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02711969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711969.